Skip to main content
. 2019 Feb 25;25(1):65–73. doi: 10.3350/cmh.2018.0070

Figure 1.

Figure 1.

Clinical study profile of additional L-carnitine treatment. This is a prospective, randomized, double-blind clinical trial study. Forty-four patients were enrolled. Three patients who withdrew consent were excluded. Twenty-two patients (group A) received sofosbuvir (SOF)+ribavirin (RBV), whereas 19 patients (group B) were treated with SOF, RBV, and L-carnitine.